Haemangioma in an infant whose mother was receiving long-term propranolol treatment during pregnancy

Méchineaud, M; Nicaise, D.; Martin, Ludovic

doi:10.1111/bjd.14235

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, a recent paper reported a male infant who presented with IH even though his mother was receiving propranolol throughout pregnancy for the treatment of mild anxiety. 23 The boy presented with several episodes of symptomatic hypoglycemia (0.6 g/L) at 3 days of age. Hypoglycemic episodes stopped after discontinuation of breastfeeding (at day 6 of age) and propranolol was considered to be responsible for the child's hypoglycemia in this case.…”

Section: Discussionmentioning

confidence: 99%

Developing a Nanoparticle-Delivered High-Efficacy Treatment for Infantile Hemangiomas Using a Mouse Hemangioendothelioma Model

Orbay

Xiao

et al. 2016

Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Background The current treatments for infantile hemangiomas (IHs) have unpredictable outcomes. The aim of this study is to develop a nanoporphyrin (NP) delivered, high-efficacy treatment for IHs using a mouse hemangioendothelioma (HT) model. Methods We injected mouse hemangioendothelioma cells intradermally to axillary regions of five-week-old, female, nude mice (n=19) to induce HT growth. We documented NP accumulation in HTs using positron emission tomography (PET). For the treatment study, we randomized HT-bearing nude mice (n=9) into three groups (n=3, each). Animals in group I received only saline injections. Animals in group II received only laser treatment after saline injection, and animals in group III received laser treatment after NP injection via tail vein. We followed up the treatment response with digital caliper measurements. Results HTs started to grow approximately one week after inoculation, and resembled IHs histologically. NP uptake in HTs was 19.7±2.2, 16.7±2.02, 8.4±0.3, and 4.9±0.6 %ID/g at 3, 6, 24, 48 hours postinjection. NP uptake in HTs was significantly higher than blood at 24 and 48 hours postinjection (p<0.05). Results of ex vivo biodistribution study were consistent with PET imaging. HTs in group III started to regress one day after the treatment and disappeared totally by day 21. The difference between tumor volumes in group III and other groups was significant on days 17, and 21 (p<0.05). Conclusion NP accumulated in HTs at high concentrations enabling a high-efficacy photodynamic therapy. Based on the similarities between HTs and IHs, this treatment potentially can be a high-efficacy treatment for IHs.

show abstract

Section: Discussionmentioning

confidence: 99%